

**ASX ANNOUNCEMENT****Actinogen presents latest Xanamem™ data at AD Conference**

- Prof Craig Ritchie, Chair of Actinogen's Xanamem Clinical Advisory Board, to present at the AAT-AD/PD international conference, held from 1st April 2020. The conference will be conducted virtually.
- Prof Ritchie's presentation summarises the key preclinical and clinical datasets and findings underpinning the therapeutic rationale and clinical potential of Xanamem:
  - Xanamem shown to be an efficacious, brain penetrant, highly selective, and potent inhibitor of the 11β-HSD1 enzyme in the brain with a validated novel mechanism of action and a strong safety profile.
  - XanaHES study confirmed a robust efficacy signal at 20mg Xanamem daily in healthy elderly, building upon previously reported outcomes observed with 10mg Xanamem daily in the XanADu study
  - Xanamem reversibly binds the 11β-HSD1 enzyme in the brain, effectively inhibiting the intracellular production of its therapeutic target cortisol
  - Phase I and II safety and efficacy data positions Xanamem for development against many diseases associated with chronically raised cortisol and cognitive impairment
  - Reducing excess cortisol levels in the brain provides a strong and rational target for further clinical development as a symptomatic and disease-modifying treatment for Alzheimer's disease
- Latest data enhances Xanamem's drug development strategy, with plans to target a broad portfolio of clinical indications of high unmet medical need and significant commercial opportunity.

**Sydney, 1 April 2020.** Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to confirm that the key findings from the latest data generated on Xanamem will be presented at the **Advancement in Alzheimer's and Parkinson's Therapies Focus Meeting (AAT-AD/PD)**, from 1<sup>st</sup> April 2020. For the first time in its history, this congress will be completely virtual, due to COVID-19 travel restrictions and health concerns.

This international scientific congress is one of the major forums reviewing the latest breakthroughs in drug development, translational R&D, early diagnosis, and clinical trials in Alzheimer's and Parkinson's disease. The global audience includes leading academic and biopharma industry experts, and this will be the first time this audience is presented with this consolidated Xanamem dataset. Professor Craig Ritchie, Chair of Actinogen's Xanamem Clinical Advisory Board, will present the data, under the title *"Chronically elevated cortisol and cognitive impairment: The therapeutic potential of Xanamem, a potent inhibitor of the 11β-HSD1 enzyme."*

Actinogen is developing Xanamem as a novel treatment for cortisol-related cognitive impairment associated with a range of indications with high unmet medical need and significant commercial opportunity. Key clinical studies have now completed, generating a substantial database on Xanamem's mechanism of action. Xanamem has shown to be an efficacious, brain penetrant, highly selective, and potent inhibitor of the 11β-HSD1 enzyme in the brain with a validated novel mechanism of action and a strong safety profile.

Actinogen continues to progress the clinical development of Xanamem, targeting a range of promising indications including new trials in Alzheimer's disease and cognitive impairment in schizophrenia and diabetes, with other indications under evaluation. This pipeline of development opportunities reflects the breadth of potential for Xanamem across a range of debilitating medical conditions. The Xanamem dataset to be presented at the AAT-AD/PD Congress is part of a larger body of data being used to inform and optimise the design of the future clinical trials.

**ENDS**

## **Actinogen Medical**

Dr. Bill Ketelbey  
CEO & Managing Director  
P: +61 2 8964 7401  
E: bill.ketelbey@actinogen.com.au  
 @BillKetelbey

## **Investor and Media Enquiries**

Arthur Chan  
WE Communications  
P: +61 2 9237 2805  
E: arthurc@we-worldwide.com

### ***Announcement authorised by the Board of Directors of Actinogen Medical***

#### **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company developing novel therapies for cognitive impairment associated with chronic neurological and metabolic diseases. The company is currently developing its lead compound Xanamem as a promising new therapy for Alzheimer's disease and cognitive impairment associated with schizophrenia and diabetes. The cognitive dysfunction associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

#### **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other therapies for Alzheimer's disease. It works by blocking the excess production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain, affecting memory. The 11β-HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease and schizophrenia and in metabolic diseases like diabetes.

The Company's XanaHES Phase I trial exploring the safety and tolerability of Xanamem 20mg once daily in healthy elderly volunteers, showed that the drug exhibited a good safety profile with no treatment-related serious adverse events. Additionally, the trial demonstrated that Xanamem produced a statistically significant improvement in cognition, which, along with other data recently generated, confirms the underlying mechanism of action of Xanamem.

The Company plans to initiate Phase II studies of Xanamem against various diseases as soon as possible after the current COVID19 health crisis affecting the globe; including in Alzheimer's disease, and in cognitive impairment associated with schizophrenia and diabetes.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

#### **Disclaimer**

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**